AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03578263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: Group (B): included 100 patients who received a combination of intraoperative oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist and
Study NCT02290327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml of 0.9% normal saline
Study NCT02427828 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visensia Respiration Rate Estimation Service (VRES)
Description: Medical device product to provide respiration rate from PPG signal
Study NCT03578263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergometrine
Description: intramuscular ergometrine 0.2 mg.
Study NCT03757715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 mL of 1.3% bupivacaine
Study NCT03757715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 2 mg dexamethasone
Study NCT01550965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study NCT06429085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rex robotic assisted balance exercises
Description: Individual is supported by a Rex robotic exoskeleton which enables assisted and supervised practise of balance exercises. This intervention took place as a supported and supervised series of 5 sessions over 5 weeks as an Out-patient.
Study NCT01649427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Hexal
Description: Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg.
Study NCT02739568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant (BF2.649)
Study NCT02739568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04251273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: This is Quitting
Description: Text message-based intervention for quit vaping support.
Study NCT04251273 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment only Control
Description: Assessment only
Study NCT01798680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
Study NCT01986023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS- Short Messaging Service
Study NCT01601561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular human insulin injection
Description: Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose.
Study NCT01798680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
Study NCT00725504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Description: Intravenous lidocaine administered up to 5 µg/ml.
Study NCT00160173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogel
Study NCT01918358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)
Study NCT01918358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)
Study NCT01918358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)
Study NCT01918358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )
Study NCT01918358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )
Study NCT01918358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)
Study NCT04426513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy with magnetotherapy
Description: Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse
Study NCT04426513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotherapy with magnetotherapy
Description: Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse
Study NCT00087672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013
Description: 10 mg orally (2 capsules) daily
Study NCT00160173 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03278080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Car-following test
Description: Driving with simulator program for DCV measurement
Study NCT00879372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tianeptine
Description: tianeptine 12,5mg TID
Study NCT00879372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 12.5 mg TID
Study NCT03712761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Enriched Protein®
Description: This product contains high quality bovine milk proteins enriched with additional leucine.
Study NCT03568123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MC polyethylene bearing
Description: Zimmer Biomet Persona Total Knee System with MC polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients >65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old.
Study NCT03568123 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CR polyethylene bearing
Description: Zimmer Biomet Persona Total Knee System with CR polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients >65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old.
Study NCT01830465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (VELCADE)
Description: 1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.
Study NCT01830465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
Study NCT02998866 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Esophageal Temperature-Guided Ablation
Description: Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI \[means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
Study NCT03713411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: urethral catheter placement
Description: urethral catheter placement to provide low-pressure urinary bladder by providing active drainage of the bladder
Study NCT00732797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-treatment booklet
Description: A booklet outlining vestibular rehabilitation exercises
Study NCT04691115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1476
Description: AM1476 Capsules
Study NCT00732797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote telephone support
Description: Up to an hour's remote support from an expert vestibular therapist
Study NCT04150939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Biopsy
Description: Undergo core biospy
Study NCT04150939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryoablation
Study NCT03278080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement
Study NCT04691115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study NCT04150939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic Agent
Description: Receive standard of care immunotherapy
Study NCT02080637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan
Description: Once daily oral dosing
Study NCT02080637 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01720836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine + PolyICLC
Description: The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
Study NCT00398879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine 50 mg/d qd
Study NCT00398879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks
Study NCT02054377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai chi
Description: Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.~It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.~A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD.
Study NCT00398879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks
Study NCT02054377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.~It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.~A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD.
Study NCT00398879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Perifosine Placebo
Description: Placebo to Perifosine 50 mg/d qd
Study NCT04317976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paralaryngeal pressure
Description: cricoid pressure with paralaryngeal pressure by fingertips applied under ultrasound guidance
Study NCT04317976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cricoid pressure
Description: cricoid pressure by fingertips applied under ultrasound guidance
Study NCT02055807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP and recruitment maneuvers
Study NCT02055807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ZEEP (no PEEP nor recruitment maneuver)
Study NCT03796533 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Posaconazole
Description: * PCZ will be used as recommended in tablet formulation at an initial dosage of 300 mg twice a day on the first day and then once a day at a dose of 300 mg the following days.~* PCZ prophylaxis will be started on the same day as the start of chemotherapy and will be continued until the end of aplasia.~* The dosage of the PCZ can be adjusted according to the results of the PCZ assay. It may be interrupted if the transaminase level is greater than 3 times higher than normal (3N) or on medical decision.
Study NCT03773380 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Breathe Anew Survivorship Program
Description: The feasibility will be tested of the Breathe Anew Survivorship Program
Study NCT00950495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Advancement Device (MAD)
Description: This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
Study NCT00950495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal CPAP
Description: The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
Study NCT00950495 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: as a placebo, a thin (\< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
Study NCT04840732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR training program
Description: Use VR software to make a training education program.
Study NCT04840732 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: Chemotherapy training as usual care (for training chemotherapy skill).
Study NCT00833716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 10 mg/mL of semaglutide solution for s.c. injection, single dose
Study NCT01674283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Study NCT01674283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00244517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl
Description: TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
Study NCT03982173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: tremelimumab 75mg
Study NCT03982173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg
Study NCT03411187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: used of the Pressure adjustable foot-control method
Description: Whether The Pressure adjustable foot-control method is used.
Study NCT03411187 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: direct exhaust
Description: direct exhaust through the trocar.
Study NCT04250207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-321 Solution
Description: K-321 solution drops
Study NCT04250207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Solution
Description: Placebo solution drops for K-321
Study NCT00244517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane, Isoflurane, Desflurane
Description: 1 MAC
Study NCT01133041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation using NBI system
Description: NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.
Study NCT01953172 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04157972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIMEOX
Description: SIMEOX is a device generating a succession of gentle depression at the mouth.
Study NCT04157972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEP
Description: A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
Study NCT01133041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation using i-Scan system
Description: I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.
Study NCT02952729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XMT-1522
Description: one intravenous dose administered in-clinic every 21 days
Study NCT03874026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfiri/Cetuximab
Description: Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered.
Study NCT02112929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized xenon
Description: Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
Study NCT01147770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: duration
Study NCT00441675 — intervention group
Intervention type: PROCEDURE
Intervention: Symptom Score
Description: Symptom Score
Study NCT00441675 — intervention group
Intervention type: PROCEDURE
Intervention: Symptom Score and PD20
Description: Symptom Score and PD20
Study NCT01077245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIYA-BM Fine Granules (CBM588)
Description: MIYA-BM Fine Granules (CBM588)
Study NCT01077245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Fine Granules (without CBM588)
Description: Placebo Fine Granules (without CBM588)
Study NCT00875628 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-00868554 or Placebo
Description: Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
Study NCT00875628 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-00868554 or Placebo
Description: Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
Study NCT00875628 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-00868554 or Placebo
Description: Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
Study NCT02138916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Arm A
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Study NCT02138916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Arm B
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Study NCT02138916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 48 inclusive
Study NCT04746820 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: single-center prospective pilot study
Description: fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~To compare fNIRS with evoked potentials there are two test phases:~1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP~2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP